Pakistan Medicines & Pharma IntelligenceMedicine data  •  Company portfolios  •  Price records
MedInfoBaseMedicines · Evidence · Intelligence
Home / Pharmaceutical company intelligence
Pharmaceutical company intelligence

The Searle Company Limited

Pharmaceutical manufacturer · Pakistan

Database-driven profile Portfolio, price and regulatory-source intelligence derived from MedInfoBase records.
ShareSend this page
Regulatory & corporate identity

Company profile

Not yet verified
Company type
Pharmaceutical manufacturer
DRAP-linked licence identifiersShown as recorded in linked source rows; not a claim of current validity.
DML 000016 171 linked products · source seen 9 Aug 2026 View source ↗
DML 000647 44 linked products · source seen 9 Aug 2026 View source ↗
Location intelligence

Company location

Google Maps
Exact site not yet verified

MedInfoBase will not invent a factory or office location. The map appears after a sourced address, Place ID or verified embed URL is added.

Open in Google Maps ↗ The Google Maps search link uses the company name and available city/country context; it is not presented as a verified premises pin.
Intelligence snapshot

Portfolio at a glance

Not sales data · current MedInfoBase database view
Rx215product presentations
G70generic molecules
DF10dosage-form groups
TA14therapeutic areas
PKR213current price records
REG166registration numbers
Data coverage

How complete is this profile?

Current price coverage99%
products with a current official price
Source-linked coverage100%
products linked back to a source record
Unit-price parse coverage100%
priced packs safely normalized per unit
Comparable-market coverage92%
products with at least one like-for-like comparator
Therapeutic classification100%
products assigned to a broad therapeutic area
Visual intelligence

Downloadable company intelligence charts

Copy or download any chart as a presentation-ready PNG. Every exported chart keeps MedInfoBase attribution and the source company-profile URL.

Shareable intelligence

Therapeutic Portfolio Mix

Shows where the company portfolio is concentrated across broad therapeutic areas.

Therapeutic Portfolio MixThe Searle Company LimitedShare of current product presentations by broad therapeutic areaMedInfoBase • medinfobase.comSource profile: medinfobase.com/company/the-searle-company-limitedGenerated 9 Aug 2026Anti-infectives81 · 38%Cardiovascular40 · 19%CNS & mental health25 · 12%Oncology & immunology13 · 6%Pain & musculoskeletal11 · 5%Hematology & thrombosis9 · 4%Respiratory & allergy8 · 4%Other therapeutic areas28 · 13%Percentages are based on current product presentations in the MedInfoBase company portfolio.

Portfolio distribution, not sales or market-share data.

Shareable intelligence

Dosage Form Portfolio

Shows how the company portfolio is distributed across tablets, capsules, injections, liquids and other forms.

Dosage Form PortfolioThe Searle Company LimitedDistribution of current product presentations by normalized dosage formMedInfoBase • medinfobase.comSource profile: medinfobase.com/company/the-searle-company-limitedGenerated 9 Aug 2026215presentationsTablet108 · 50%Injection46 · 21%Suspension27 · 13%Capsule18 · 8%Infusion4 · 2%Syrup4 · 2%Other forms8 · 4%Dosage-form wording is normalized for intelligence display; original source wording remains preserved in product records.

Counts are product presentations, not production or sales volumes.

Shareable intelligence

Equivalent-Market Price Position

Shows whether safely comparable products are below, near or above the market median unit price.

Equivalent-Market Price PositionThe Searle Company LimitedCurrent company products compared with like-for-like equivalent medicines using normalized unit pricesMedInfoBase • medinfobase.comSource profile: medinfobase.com/company/the-searle-company-limitedGenerated 9 Aug 2026197comparable productsBelow market median16 · 8%Near market median97 · 49%Above market median84 · 43%Company median price position+4.3%Lowest-price equivalents17Method: same generic + stated strength + dosage form + compatible unit basis; pack prices normalized per unit.

This is price-position intelligence, not sales, demand or market-share data.

Shareable intelligence

Closest Portfolio Competitors

Highlights other manufacturers with the greatest generic overlap with this company portfolio.

Closest Portfolio CompetitorsThe Searle Company LimitedCompanies with the largest number of shared generic medicines in the MedInfoBase databaseMedInfoBase • medinfobase.comSource profile: medinfobase.com/company/the-searle-company-limitedGenerated 9 Aug 2026M/s. Genix Pharma (Pvt) Ltd.40 shared57% overlapBosch Pharmaceuticals (Pvt) Ltd.40 shared57% overlapMacter International Limited40 shared57% overlapHigh-Q Pharmaceuticals35 shared50% overlapNabiqasim Industries (Pvt) Ltd.,34 shared49% overlapWerrick Pharmaceuticals34 shared49% overlapPortfolio overlap measures shared generics only; it is not a measure of market share, affiliation or sales competition.

Competitor ranking is based on shared generics in MedInfoBase, not commercial sales performance.

Portfolio intelligence

Therapeutic areas

Broad portfolio view

High-level clinical areas represented by this company’s current MedInfoBase portfolio.

Anti-infectives81 products · 38%
Cardiovascular40 products · 19%
CNS & mental health25 products · 12%
Oncology & immunology13 products · 6%
Pain & musculoskeletal11 products · 5%
Hematology & thrombosis9 products · 4%
Respiratory & allergy8 products · 4%
Gastrointestinal & hepatology8 products · 4%
Pharmacological detail

Drug classes

More specific view

More specific classes derived from the canonical generic and preserved curated classifications.

Penicillin antibacterials23 products · 11%
Calcium-channel blockers17 products · 8%
Antineoplastic medicines12 products · 6%
Antivirals11 products · 5%
Antiepileptics11 products · 5%
Analgesics / NSAIDs11 products · 5%
Third-generation cephalosporins10 products · 5%
Antipsychotics10 products · 5%
Formulation footprint

Dosage forms

Tablet108 products
Injection46 products
Suspension27 products
Capsule18 products
Infusion4 products
Syrup4 products
Inhalation3 products
Drops2 products
Sachet2 products
Solution1 products
How MedInfoBase classifies the portfolio

MedInfoBase uses a two-level taxonomy. Therapeutic area is a broad portfolio category, while drug class is the more specific pharmacological or clinical class. Existing curated classifications are preserved. Blank records are assigned conservatively from the canonical generic name and, when available, ATC information. Multi-use medicines may be placed in a cross-therapeutic category rather than forced into a single indication.

Portfolio leaders

Deepest brand families

Ranked by registered presentations · not sales
#1 SerenaceHaloperidol 10presentations 0.25 mg, 1.5 mg, 10 mg, 2 mg/mL · Tablet, Injection #2 Telnip-ATelmisartan + Amlodipine 9presentations 10 mg + 40 mg, 10 mg + 80 mg, 5 mg + 40 mg, 5 mg + 80 mg · Tablet #3 ZeemoxAmoxicillin 8presentations 1000 mg, 125 mg/5 mL, 250 mg, 250 mg/5 mL · Tablet, Suspension, Capsule #4 FortecinAmoxicillin + clavulanic acid 7presentations 1000 mg + 200 mg, 125 mg + 31.25 mg / 5 mL, 250 mg + 125 mg, 50 mg + 12.5 mg / mL · Injection, Suspension, Tablet #5 LumarkLevetiracetam 7presentations 100 mg/mL, 1000 mg, 250 mg, 500 mg · Solution, Tablet, Injection #6 SuscardNitroglycerin 6presentations 2 mg, 5 mg · Tablet
Price intelligence

Unit-price positioning vs equivalent products

Same generic + strength + form + unit basis
Below market median168% of comparable products
Near market median97within ±5% of median
Above market median8443% of comparable products
Lowest-price equivalents17ties included
Company median price position +4.3% relative to the median unit price of like-for-like equivalent products.
Most competitively positioned examplesProducts with at least 3 market comparators
Nezolid 600 mgLinezolid · Tablet · 12's PKR 155.32/tablet-60.5% vs market median Lenava 25 mgLenalidomide · Capsule · 1x7's PKR 1,116.00/capsule-33.4% vs market median Lenava 10 mgLenalidomide · Capsule · 1x7’s PKR 506.57/capsule-33.4% vs market median Anzica 250 mg/5 mLTranexamic acid · Injection · 10's PKR 49.05/vial/unit-23.3% vs market median Aforbs 10 mgAmlodipine · Tablet · 20's PKR 13.99/tablet-19.5% vs market median
How MedInfoBase calculates price position

Only current prices with safely interpretable pack quantities are used. A product is compared only with the same generic, same stated strength, same dosage form and a compatible unit basis such as tablet, capsule, mL or gram. These are database-derived price comparisons, not sales or market-share estimates.

Competitive landscape

Portfolio overlap

Companies sharing the largest number of generics with this portfolio. This measures product overlap, not commercial performance.

M/s. Genix Pharma (Pvt) Ltd.290 products · 97 generics 40shared generics Bosch Pharmaceuticals (Pvt) Ltd.250 products · 73 generics 40shared generics Macter International Limited248 products · 91 generics 40shared generics High-Q Pharmaceuticals196 products · 59 generics 35shared generics Nabiqasim Industries (Pvt) Ltd.,362 products · 118 generics 34shared generics Werrick Pharmaceuticals249 products · 82 generics 34shared generics
Regulatory & price activity

Observed database signals

Registration numbers166
Price-history records255
Products with price history29
Source records with multiple versions0
Latest MedInfoBase verification9 Aug 2026
Latest effective price date4 Aug 2026
Latest source observation9 Aug 2026

These dates describe records observed by MedInfoBase. They should not be interpreted as product launch dates or sales activity.

Sponsored company campaign area · advertising must be clearly disclosed
Complete company portfolio

Products and presentations

11 results
Intelligence filter: Drug classAntiepileptics Clear intelligence filters
Reset
BrandGenericStrengthFormPackRegistrationOfficial priceUnit priceMarket position
Lamnet Lamotrigine = 25 mg Tablet 30’s 042248 PKR 648.67 PKR 21.62/tablet Near median
Lamnet Lamotrigine = 50 mg Tablet 30’s 042249 PKR 864.88 PKR 28.83/tablet Near median
Lamnet Lamotrigine = 100 mg Tablet 30’s 042250 PKR 1,081.10 PKR 36.04/tablet Near median
Lamnet Lamotrigine = 5 mg Chewable tablet 30's 053114 PKR 125.84 PKR 4.19/tablet No comparator
Lumark Levetiracetam 250 mg Tablet 30’s 054506 PKR 2,096.03 PKR 69.87/tablet 26% above median
Lumark Levetiracetam 500 mg Tablet 30’s 054507 PKR 3,427.64 PKR 114.25/tablet 21% above median
Lumark Levetiracetam 750 mg Tablet 10’s 069065 PKR 1,620.11 PKR 162.01/tablet 24% above median
Lumark Levetiracetam 500 mg Extended-release tablet 10’s 085930 PKR 1,122.88 PKR 112.29/tablet Near median
Lumark Levetiracetam 1000 mg Tablet 10’s 069064 PKR 1,854.69 PKR 185.47/tablet 21% above median
Lumark Levetiracetam 500 mg/5 mL Injection 1's 075873 PKR 695.37 PKR 695.37/vial/unit 13% above median
Lumark Levetiracetam 100 mg/mL Oral solution 60 ml 063168 PKR 887.74 PKR 14.80/mL 10% above median
MedInfoBase company-intelligence methodology

This page is generated from MedInfoBase medicine, generic, company, price and DRAP-source records. Portfolio leaders are ranked by presentation depth, not sales. Price-position metrics are calculated from current official prices normalized to compatible units and compared only against like-for-like products with the same generic, stated strength and dosage form.

Not currently included: sales volume, revenue by brand, market share, prescription volume or best-selling rankings. MedInfoBase will display those only when supported by a defensible licensed, public or company-verified source.